March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Disappearance of Drusen after Intravitreal Anti-VEGF Injections for Submacular Hemorrhage (SMH) Secondary To Neovascular Macular Degeneration (n-AMD)
Author Affiliations & Notes
  • Kamal Kishore
    Illinois Retina Institute, Peoria, Illinois
    Surgery-Ophthalmology, UICollege of Medicine-Peoria Campus, Peoria, Illinois
  • Sachin Jain
    Illinois Retina Institute, Peoria, Illinois
  • Yog R. Sharma
    Vitreo-Retinal Surgery, Dr. R.P. Centre for Ophthalmic Sciences, AIIMS, New Delhi, India
  • Bharti Kashyap
    Kashyap Memorial Eye Hospital, Ranchi, India
  • Footnotes
    Commercial Relationships  Kamal Kishore, None; Sachin Jain, None; Yog R. Sharma, None; Bharti Kashyap, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2912. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kamal Kishore, Sachin Jain, Yog R. Sharma, Bharti Kashyap; Disappearance of Drusen after Intravitreal Anti-VEGF Injections for Submacular Hemorrhage (SMH) Secondary To Neovascular Macular Degeneration (n-AMD). Invest. Ophthalmol. Vis. Sci. 2012;53(14):2912.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To report rapid regression of drusen in 3 eyes with acute SMH secondary to n-AMD treated with anti-VEGF injections.


Retrospective chart review of 3 eyes of 3 patients (age 63,86 and 85 yrs, all F) presenting with central scotoma of ≤ 7 days secondary to SMH from n-AMD. Inclusion criteria: availability of color fundus photos obtained ≤1 year prior to onset of SMH, multiple, large (soft) drusen on those photos, clear media and follow up > one yr. Exclusion criteria: symptoms ≥7days, treatment other than anti-VEGF injections, pre-existing subretinal fibrosis or GA, and non-AMD SMH. After initial work up including IVFA and OCT, monthly injections of bevacizumab 1.25 mg/0.05mL (2 eyes) or 0.5 mg/0.05mL ranibizumab (1 eye) were initiated until resolution of SMH, and less frequently thereafter. Fundus photos obtained after resolution of SMH were compared side-by-side with those prior to onset of SMH for change in soft drusen, and other findings.


Lesion size ranged from 12.2-91 mm2. SMH resolved in all eyes in 4,5 and 11 months respectively without subretinal fibrosis. Marked (>90%) regression of drusen was observed in each eye compared to pre-SMH photos (Figure 1: OD of Case 1 six month prior to SMH. Figure 2: Same eye 4 month after SMH showing resolution of SMH and marked regression of drusen). RPE hypopigmentation, but no GA was also noted in one eye. Occult CNVM was noted in each eye. Final VA improved to 20/30, 20/50 and 20/40 from the baseline of 20/50, HM and CF.


Soft drusen may regress rapidly in patients with SMH treated with anti-VEGF injections, most likely due to phagocytosis of drusen material by macrophages and multinucleated giant cells.  


Keywords: age-related macular degeneration • injection • vascular endothelial growth factor 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.